Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how the body and the cancer react to carfilzomib,
including measuring the amount of the study drug in the blood at certain times following
dosing. This study is being done in people with normal kidney function and those with
end-stage renal disease to see if they respond differently to the study drug.